Krystal Biotech, Inc. (KRYS) Balance Sheet

The rapid accumulation of retained earnings suggests that the company has moved past its initial capital-intensive phase and is now generating self-sustaining growth. This trajectory implies that the business model is successfully scaling, providing a solid foundation for future pipeline investments without the immediate need for external financing.

The current ratio of 9.46 indicates an exceptionally high level of short-term liquidity, which suggests the company is well-positioned to navigate potential market volatility or unexpected operational disruptions. This liquidity buffer appears more than sufficient to support ongoing commercial activities and planned clinical development programs.

This asset-heavy approach to manufacturing appears to be a key driver of the company's high gross margins, as it allows for greater control over production quality and supply chain reliability. Investors should monitor whether this infrastructure remains sufficient as the company expands into more complex inhaled delivery indications.

The near-total absence of debt suggests that management is prioritizing financial independence and avoiding the constraints of restrictive covenants. This lack of leverage implies that the company's growth is being funded entirely through internal cash generation, which is a positive indicator of long-term financial durability.